Press Releases

InVivo Therapeutics Announces Presentation of Complete Six-Month Primary Endpoint Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury

Published: May 2, 2018

– Findings Presented at the 2018 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting – CAMBRIDGE, Mass. (May 2, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the presentation of the complete six-month primary endpoint results from the company’s single-arm The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at a medical meeting. The presentation was given by Stuart Lee, M.D., Division of Neurosurgery, Vidant Health, at the 2018 AANS Meeting during the Plenary Session II on Tuesday, May […]

View Article
InVivo Therapeutics Provides Business Update

Published: April 9, 2018

Announces Reverse Stock Split and Key Cost-Saving Initiatives CAMBRIDGE, Mass. (April 9, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today provided a general business update.  The company is announcing a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. The company anticipates the reverse stock split will become effective at 5:00 p.m. Eastern Time on April 16, 2018, and shares of InVivo Therapeutics common stock will trade on a post-split basis under the Company’s existing trading symbol, “NVIV,” at the market open on April 17, 2018. The new CUSIP number for […]

View Article
InVivo Therapeutics Announces Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”) Findings

Published: March 19, 2018

-Validates previously established Objective Performance Criterion (OPC) – CAMBRIDGE, Mass. (March 19, 2018) – InVivo Therapeutics Holdings Corp. (NVIV) today announced top-line findings from its CONTEMPO Registry Study, designed to provide comprehensive natural history benchmarks for Neuro-Spinal Scaffold™ clinical study results. The CONTEMPO study includes neurological recovery data from registries of spinal cord injury (SCI) patients with similar baseline characteristics to those in the INSPIRE study.  Specifically, only patients injured between 2006 and 2016 and meeting inclusion and exclusion criteria similar to those in INSPIRE were included.  Examples of such criteria include age (16-70 years), T2-T12 neurological level of injury (NLI), […]

View Article
InVivo Therapeutics Reports 2017 Year-end Financial Results

Published: March 12, 2018

CAMBRIDGE, Mass. (March 12, 2018) – InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2017. Richard Toselli, M.D., President and Chief Executive Officer of InVivo, commented, “InVivo is charting a new and exciting path forward based on collaboration with the FDA that has continued through 2017 and into this year. We were pleased to announce last week that we received the agency’s approval of our supplemental Investigational Device Exemption (IDE) to initiate a second pivotal study of the company’s Neuro-Spinal Scaffold™ in patients with acute spinal cord injury (SCI). We believe this second […]

View Article
InVivo Therapeutics Receives FDA Approval for Pivotal, Randomized, Controlled Trial of the Neuro-Spinal Scaffold™ in Patients with Acute Spinal Cord Injury

Published: March 8, 2018

Study Designed to Enhance Clinical Evidence from INSPIRE Study and Support Potential Humanitarian Device Exemption (HDE) Submission CAMBRIDGE, Mass. (March 8, 2018) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company has received supplemental Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) for a second pivotal clinical study of the company’s Neuro-Spinal Scaffold™ in patients with acute spinal cord injury (SCI). The 20-patient (10 subjects in each study arm), randomized, controlled trial is designed to enhance the existing clinical evidence for the Neuro-Spinal Scaffold™ from the company’s single-arm  INSPIRE study (InVivo Study of Probable Benefit […]

View Article
InVivo Therapeutics Announces Appointment of Richard Toselli, M.D., as President and Chief Executive Officer

Published: February 5, 2018

Dr. Toselli Also Joins Board of Directors, Retains Position as InVivo’s Chief Medical Officer CAMBRIDGE, Mass. (February 5, 2018) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Richard Toselli, M.D., has been appointed President and Chief Executive Officer of InVivo, having been appointed the company’s Acting CEO in December 2017. Dr. Toselli also has been appointed to the company’s Board of Directors and will continue to serve in his capacity as InVivo’s Chief Medical Officer, which role he assumed upon joining the company in July 2017. Dr. Toselli, a Board-certified neurosurgeon, has led an accomplished career in surgical medical […]

View Article
InVivo Therapeutics Announces Purchase Agreement for up to $15 Million with Lincoln Park Capital

Published: January 26, 2018

CAMBRIDGE, Mass. (Jan 26, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”), a Chicago-based institutional investor, under which the Company has the right to sell up to $15 million in shares of common stock to Lincoln Park over a twenty-four-month period, subject to certain limitations and conditions set forth in the purchase agreement and registration rights agreement, including: the company, in its sole discretion, controls the timing and amount of any sales of common stock; the purchase price is based on […]

View Article
InVivo Therapeutics Announces Latest Results from INSPIRE and Provides Update on Proposed Clinical Path Forward

Published: January 3, 2018

CAMBRIDGE, Mass. (Jan 3, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the latest results from The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury).  The primary endpoint of the study is defined as improvement in ASIA Impairment Scale (AIS) grade from baseline for all evaluable patients at the six-month visit. Nineteen patients have been implanted with the Neuro-Spinal Scaffold. Three patients died within two weeks of implantation. The 16 evaluable patients have now all reached the six-month primary endpoint visit. […]

View Article
InVivo Therapeutics Announces Executive Management and Board Changes

Published: December 18, 2017

Richard Toselli, M.D., Named Acting Chief Executive Officer Ann Merrifield Named Chair CAMBRIDGE, Mass. (December 18, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Richard Toselli, M.D., has been appointed Acting Chief Executive Officer of InVivo, replacing Mark D. Perrin, who has resigned as Chief Executive Officer and Chairman of InVivo’s Board of Directors. Dr. Toselli, a Board-certified neurosurgeon possessing senior leadership experience in surgical medical affairs at firms including Sanofi, DePuy, and Johnson & Johnson, will continue to serve in his capacity as InVivo’s Chief Medical Officer, which role he assumed upon joining the Company in July […]

View Article
InVivo Therapeutics to Present at Canaccord Genuity’s Medical Technologies & Diagnostics Forum

Published: November 6, 2017

CAMBRIDGE, Mass. (November 6, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the upcoming Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 9, 2017 at 3:00 PM Eastern Time at the Westin New York Grand Central Hotel in Manhattan. Mr. Perrin will present an overview of the company’s Neuro-Spinal Scaffold™ program and discuss other recent business updates for the company during the presentation. About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.